Ankylosing Spondylitis Market Size Is Predicted To Reach $7.9 Billion By 2027

The global ankylosing spondylitis market size is expected to reach USD 7.9 billion by 2027 registering a CAGR of 8.3%, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province’s public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Full Research Report On Ankylosing Spondylitis Market Visit Here: https://www.grandviewresearch.com/industry-analysis/ankylosing-spondylitis-market

Ankylosing Spondylitis Market Report Highlights

• Humira was the largest revenue-generating drug in 2019 and accounted for over 25% of the market share due to the favorable pricing and lack of biosimilar competition in North America
• Cosentyx is estimated to be the fastest-growing segment due to its excellent clinical profile. In addition, the product is patent protected for ankylosing spondylitis till 2033 in U.S. till and 2030 in Europe
• North America led the market in 2019 due to the presence of key biopharmaceutical & pharmaceutical companies and increased funding and research initiatives
• Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
• For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/ankylosing-spondylitis-market/request/rs1

Ankylosing Spondylitis Market Segmentation

Grand View Research has segmented the global ankylosing spondylitis market based on drug and region:

Ankylosing Spondylitis Drug Outlook (Revenue, USD Million, 2016 - 2027)

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia
• Others

Ankylosing Spondylitis Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Chile
• Columbia
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players of Ankylosing Spondylitis Market

• AbbVie, Inc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• UCB, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com